Ellison Institute

EITM Discussion Series

Dr. Clesson Turner, M.D.

Director, Reverse Phenotyping Core
Staff Clinician, Center for Precision Health Research

Predictive Medicine Research Through Reverse Phenotyping

Tuesday, Oct. 25, 2022
9:30–10:30 a.m. PST

Leonardo Auditorium

Zoom Link: https://eitm-org.zoom.us/j/98456573077?from=addon

Dr. Clesson Turner is a staff clinician and Director of the National Human Genome Research Institute's (NHGRI) Reverse Phenotyping Core. He received a B.S. from the University of Notre Dame and attended medical school at the University of Vermont College of Medicine. Following medical school, he completed a residency in pediatrics through the National Capital Consortium in 2002 and a residency in Clinical Genetics and Clinical Molecular Genetics at NHGRI in 2009. Dr. Turner served as the Chief of Genetics at Walter Reed National Military Medical Center and as the Chief of Cancer Genetics at the Murtha Cancer Center prior to retiring from the U.S. Army in 2019. After, he was an associate professor in pediatrics and the interim director for precision medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD.

In 2021, Dr. Turner joined NHGRI to direct its Reverse Phenotyping Core in the Center for Precision Health Research. He oversees the daily operations of the core and supervises three core personnel. His major focus is the development and implementation of reverse phenotyping protocols to advance the clinical impact of genomic medicine.

In this talk, Dr. Turner will provide an overview of Reverse Phenotyping, which uses a genotype-first approach to test gene-disease relationships by interrogating whether individuals with specific genetic variants have a shared hypothesized phenotype. With Reverse Phenotyping, you can: 1) identify research participants with a variant of interest; 2) test novel gene-disease associations; 3) expand the phenotypic spectrum of disease; and 4) advance precision health research.

Host: jerry@eitm.org